This Article Full Text Full Text (PDF) All Versions of this Article: 108/4/420    most recent 01.CIR.0000080884.27358.49v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Anand, S. S. Articles by Yusuf, S. Search for Related Content PubMed PubMed Citation Articles by Anand, S. S. Articles by Yusuf, S. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Metabolic Syndrome Related Collections Epidemiology Type 2 diabetes Glucose intolerance Pathophysiology Risk Factors Fibrinolysis

(Circulation. 2003;108:420.)
© 2003 American Heart Association, Inc.

Clinical Investigation and Reports

Relationship of Metabolic Syndrome and Fibrinolytic Dysfunction to Cardiovascular Disease

Sonia S. Anand, MD, PhD; Qilong Yi, MSc; Hertzel Gerstein, MD; Eva Lonn, MD; Ruby Jacobs, RN; Vlad Vuksan, PhD; Koon Teo, MBBS; Bonnie Davis, RN; Patty Montague, MSc; Salim Yusuf, DPhil, for the Study of Health Assessment and Risk in Ethnic groups (SHARE) and Study of Health Assessment and Risk Evaluation in Aboriginal Peoples (SHARE-AP) Investigators

From the Department of Medicine, McMaster University (S.S.A., H.G., E.L., K.T., P.M., S.Y.), Hamilton, Canada; Population Health Research Institute, Hamilton Health Sciences and McMaster University (S.S.A., Q.Y., H.G., E.L., K.T., P.M., S.Y.), Hamilton, Canada; Six Nations Health Services (R.J., B.D.), Ohsweken, Canada; and University of Toronto (V.V.), Toronto, Canada.

Correspondence to Dr Sonia Anand, McMaster Clinic Room 522, Hamilton General Hospital, 237 Barton St East, Hamilton, Ontario L8L 2X2, Canada.

Received November 19, 2002; de novo received February 24, 2003; revision received April 29, 2003; accepted May 2, 2003.

Background— The clustering of impaired glucose metabolism, elevated triglycerides, low HDL cholesterol, and abdominal obesity is known as the metabolic syndrome. Individuals with this syndrome suffer an excess of cardiovascular disease (CVD) for reasons that are unclear.

Methods and Results— We randomly sampled 1276 adults of South Asian, Chinese, European, and Native Indian ancestry from 4 communities in Canada. Participants provided fasting blood samples for glucose, lipids, and fibrinolytic measurements; had an oral glucose tolerance test; and underwent a B-mode carotid ultrasound examination. CVD was determined by history and ECG. The prevalence of the metabolic syndrome was 25.8% (95% CI, 23.5 to 28.2) and varied substantially by ethnic group: 41.6% among Native Indians, 25.9% among South Asians, and 22.0% among Europeans, compared with 11.0% among the Chinese (overall, P=0.0001). People with the metabolic syndrome had more atherosclerosis (maximum intimal medial thickness, 0.78±0.18 versus 0.74±0.18 mm; P=0.0005), CVD (17.2% versus 7.0%; P=0.0001), and elevated plasminogen activator inhibitor-1 (24.2 versus 14.6 U/mL; P=0.001) compared with levels among people without the metabolic syndrome. For the same amount of atherosclerosis, people with the metabolic syndrome had a greater prevalence of CVD, even among nondiabetic individuals. This difference in CVD prevalence among the groups was attenuated after adjustment for plasminogen activator inhibitor-1 levels, suggesting that fibrinolytic dysfunction mediates the increased risk of CVD in individuals with the metabolic syndrome.

Conclusion— CVD among people with the metabolic syndrome is explained by their excess of atherosclerosis and impaired fibrinolysis. Interventions to prevent atherosclerosis progression and improve fibrinolytic function require evaluation in this high-risk group.

Key Words: diabetes mellitus • atherosclerosis • fibrinolysis • epidemiology

This article has been cited by other articles:

				G. P. Van Guilder, G. L. Hoetzer, J. J. Greiner, B. L. Stauffer, and C. A. DeSouza Metabolic syndrome and endothelial fibrinolytic capacity in obese adults Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2008; 294(1): R39 - R44. [Abstract] [Full Text] [PDF]

				P.E. Morange, N. Saut, M.C. Alessi, J.S. Yudkin, M. Margaglione, G. Di Minno, A. Hamsten, S.E. Humphries, D.A. Tregouet, and I. Juhan-Vague Association of Plasminogen Activator Inhibitor (PAI)-1 (SERPINE1) SNPs With Myocardial Infarction, Plasma PAI-1, and Metabolic Parameters: The HIFMECH Study Arterioscler. Thromb. Vasc. Biol., October 1, 2007; 27(10): 2250 - 2257. [Abstract] [Full Text] [PDF]

				M.-C. Alessi and I. Juhan-Vague PAI-1 and the Metabolic Syndrome: Links, Causes, and Consequences Arterioscler. Thromb. Vasc. Biol., October 1, 2006; 26(10): 2200 - 2207. [Abstract] [Full Text] [PDF]

				L. E. Eberly, R. Prineas, J. D. Cohen, G. Vazquez, X. Zhi, J. D. Neaton, L. H. Kuller, and for the Multiple Risk Factor Intervention Trial Re Metabolic Syndrome: Risk factor distribution and 18-year mortality in the Multiple Risk Factor Intervention Trial Diabetes Care, January 1, 2006; 29(1): 123 - 130. [Abstract] [Full Text] [PDF]

				C. J. Girman, J. M. Dekker, T. Rhodes, G. Nijpels, C. D. A. Stehouwer, L. M. Bouter, and R. J. Heine An Exploratory Analysis of Criteria for the Metabolic Syndrome and Its Prediction of Long-term Cardiovascular Outcomes: The Hoorn Study Am. J. Epidemiol., September 1, 2005; 162(5): 438 - 447. [Abstract] [Full Text] [PDF]

				C. Irace, C. Cortese, E. Fiaschi, C. Carallo, G. Sesti, E. Farinaro, and A. Gnasso Components of the Metabolic Syndrome and Carotid Atherosclerosis: Role of Elevated Blood Pressure Hypertension, April 1, 2005; 45(4): 597 - 601. [Abstract] [Full Text] [PDF]

				D. Simmons and C. F. Thompson Prevalence of the Metabolic Syndrome Among Adult New Zealanders of Polynesian and European Descent Diabetes Care, December 1, 2004; 27(12): 3002 - 3004. [Full Text] [PDF]

				A. Raji, M. D. Gerhard-Herman, M. Warren, S. G. Silverman, V. Raptopoulos, C. S. Mantzoros, and D. C. Simonson Insulin Resistance and Vascular Dysfunction in Nondiabetic Asian Indians J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3965 - 3972. [Abstract] [Full Text] [PDF]

				S. S. Anand, F. Razak, Q. Yi, B. Davis, R. Jacobs, V. Vuksan, E. Lonn, K. Teo, M. McQueen, and S. Yusuf C-Reactive Protein as a Screening Test for Cardiovascular Risk in a Multiethnic Population Arterioscler. Thromb. Vasc. Biol., August 1, 2004; 24(8): 1509 - 1515. [Abstract] [Full Text] [PDF]

				D. Prabhakaran and S. S Anand The metabolic syndrome: an emerging risk state for cardiovascular disease Vascular Medicine, February 1, 2004; 9(1): 55 - 68. [Abstract] [PDF]

				V. Fonseca, C. Desouza, S. Asnani, and I. Jialal Nontraditional Risk Factors for Cardiovascular Disease in Diabetes Endocr. Rev., February 1, 2004; 25(1): 153 - 175. [Abstract] [Full Text] [PDF]

				D. J. Kereiakes and J. T. Willerson Metabolic Syndrome Epidemic Circulation, September 30, 2003; 108(13): 1552 - 1553. [Full Text] [PDF]